Nu-Med Plus (NUMD) Cash from Operations Growth (3y) (2015 - 2025)
Nu-Med Plus (NUMD) Cash from Operations Growth (3y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.28 Bn | 193.68 Bn | 7.27 Bn | 27.41% |
| 2 | Stryker | 129.49 Bn | 126.02 Bn | 4.50 Bn | 22.38% |
| 3 | Medtronic | 119.55 Bn | 110.33 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 73.67 Bn | 73.13 Bn | 3.85 Bn | 30.85% |
| 5 | Edwards Lifesciences | 52.28 Bn | 48.03 Bn | 1.35 Bn | 168.71% |
| 6 | Dexcom | 34.62 Bn | 32.67 Bn | 830.00 Mn | 12.26% |
| 7 | GE HealthCare Technologies | 34.13 Bn | 32.02 Bn | 2.18 Bn | 65.19% |
| 8 | Koninklijke Philips | 26.42 Bn | 23.10 Bn | 4.55 Bn | 43.79% |
| 9 | Steris | 23.17 Bn | 22.69 Bn | 684.20 Mn | 9.30% |
| 10 | Nu-Med Plus | 2.03 Mn | 2.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12.79% |
| Sep 30, 2025 | -172.24% |
| Dec 31, 2024 | 56.43% |
| Jun 30, 2024 | 67.34% |
| Mar 31, 2024 | 82.16% |
| Dec 31, 2023 | 60.83% |
| Sep 30, 2023 | 42.84% |
| Jun 30, 2023 | 46.10% |
| Mar 31, 2023 | 40.39% |
| Dec 31, 2022 | 41.91% |
| Sep 30, 2022 | 26.17% |
| Jun 30, 2022 | 72.39% |
| Mar 31, 2022 | 63.36% |
| Dec 31, 2021 | 47.99% |
| Sep 30, 2021 | 34.05% |
| Jun 30, 2021 | 12.61% |
| Mar 31, 2021 | 1.04% |
| Dec 31, 2020 | 20.00% |
| Sep 30, 2020 | 7.55% |
| Jun 30, 2020 | -18.03% |